STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem

With sales growth slowing, the company’s stock price has tumbled Kristoffer Tripplaar/Sipa USA/AP Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content. Accountability check: Let’s talk about my “Alnylam is the next Vertex” take from the Aug. 7, 2025, edition of this newsletter. Alnylam and Vertex are not direct competitors, but I was intrigued by the possibility that Alnylam’s rapidly accelerating growth — fueled by sales of its blockbuster cardiomyopathy treatment Amvuttra — could push its $60 billion market value equal to or higher than Vertex’s $100 billion market cap in the near future. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.